WS #13303
FT reports AstraZeneca in $400B merger talks with Bristol Myers Squibb; AZN shares drop ~6-7% on deal risk and regulatory hurdles.
AstraZeneca-BMS merger talks
FT reports AstraZeneca in $400B merger talks with Bristol Myers Squibb; AZN shares drop ~6-7% on deal risk and regulatory hurdles.